[Gene therapy of primary cancers of the liver: hopes and realities].
Many efforts have been devoted to the development of gene therapy for primary liver tumors. This has been hampered by the absence of efficient gene transfer vectors for delivering genes into hepatoma cells in vivo. Also it remains to determine which type of gene has to be used to achieve complete tumor regression. Recent studies have documented improvements obtained using recombinant adenoviral vectors carrying the herpes simplex virus thymidine kinase gene as well as the ability to specifically target gene expression into the tumor cells by using the alpha-fetoprotein gene regulatory sequence. Therefore it seems reasonable to expect the development of clinical protocols in the near future.
Ferry
N
N
Laboratoire de transfert de gènes, INSERM U. 49, Centre, Eugène-Marquis, Rennes, France.
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D015774:Ganciclovir / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods / Q000639:trends; D005822:Genetic Vectors; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D051379:Mice; D051381:Rats; D012190:Retroviridae / Q000235:genetics; D018139:Simplexvirus / Q000235:genetics; D000509:alpha-Fetoproteins / Q000235:genetics
D019496:Cancer Vaccines; D000509:alpha-Fetoproteins; D015774:Ganciclovir
La thérapie génique des cancers primitifs du foie: espoirs et réalités.